Literature DB >> 3782792

Localization of biologic functions of toxic shock syndrome toxin-1 by use of monoclonal antibodies and cyanogen bromide-generated toxin fragments.

D A Blomster-Hautamaa, R P Novick, P M Schlievert.   

Abstract

Monoclonal antibodies (mAb) against toxic shock syndrome toxin-1 (TSST-1) were generated that block two of the most important biologic activities of TSST-1, nonspecific T lymphocyte mitogenicity and the suppression of immunoglobulin synthesis. Fourteen hybridomas producing antibody against TSST-1 were isolated independently. The culture supernatant and ascitic fluids from each were analyzed to determine the mAb isotypes. Seven of the mAb were IgG1, and the remaining seven were IgM; all the mAb had kappa light chains. Immunoglobulin was partially purified from hybridoma-generated ascitic fluid by ammonium sulfate precipitation and tested for the ability to block TSST-1-induced mitogenicity and immunosuppression. Three mAb (all IgG1) were shown to block both the toxin-induced mitogenicity and the suppression. None of the mAb tested inhibited just one of the two toxin activities. The neutralizing mAb were then used in Western analysis with previously mapped cyanogen bromide (CNBr)-generated toxin fragments to localize the aforementioned biologic functions. The Western blot analysis showed that the mitogenic and the suppressive functions of TSST-1 were located on a 14,000 dalton internal CNBr fragment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3782792

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Residues 20, 22, and 26 determine the subtype specificities of staphylococcal enterotoxins C1 and C2.

Authors:  T N Turner; C L Smith; G A Bohach
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

2.  Effect of chemical modification of histidine and tyrosine residues in toxic shock syndrome toxin 1 on the serologic and mitogenic activities of the toxin.

Authors:  N P Kokan-Moore; M S Bergdoll
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

3.  Cross-neutralization of staphylococcal and streptococcal pyrogenic toxins by monoclonal and polyclonal antibodies.

Authors:  G A Bohach; C J Hovde; J P Handley; P M Schlievert
Journal:  Infect Immun       Date:  1988-02       Impact factor: 3.441

4.  Identification of functional antigenic segments of toxic shock syndrome toxin 1 by differential immunoreactivity and by differential mitogenic responses of human peripheral blood mononuclear cells, using active toxin fragments.

Authors:  C Edwin; E H Kass
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

5.  Biological and immunological properties of the carboxyl terminus of staphylococcal enterotoxin C1.

Authors:  G A Bohach; J P Handley; P M Schlievert
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

Review 6.  Bacterial pyrogenic exotoxins as superantigens.

Authors:  M Kotb
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

7.  Localization of biologically important regions on toxic shock syndrome toxin 1.

Authors:  D L Murray; C A Earhart; D T Mitchell; D H Ohlendorf; R P Novick; P M Schlievert
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

8.  Concomitant loss of conformation and superantigenic activity of staphylococcal enterotoxin B deletion mutant proteins.

Authors:  B Metzroth; T Marx; M Linnig; B Fleischer
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

9.  Production of toxic shock syndrome-like illness in rabbits by Staphylococcus aureus D4508: association with enterotoxin A.

Authors:  B D McCollister; B N Kreiswirth; R P Novick; P M Schlievert
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

10.  Rapid assay for detection of toxic shock syndrome toxin 1 from human sera.

Authors:  K Miwa; M Fukuyama; T Kunitomo; H Igarashi
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.